HOPA Virtual Practice Management Series
New in 2026: FREE Virtual Practice Management Sessions
Designed to Keep Practice Managers, Managing Their Practice
What if you could get practice management learning without leaving your practice for the day? Now you can! HOPA’s Virtual Practice Management (PM) Series brings educational content and continuing education (CE) credits to you four times a year - and now it's FREE for HOPA members!
Our Virtual Practice Management Series:
- Provides single-topic, 60-90-minute webinars
- Makes live CE credits available more frequently
- Creates a consistent flow of timely practice management learning
- Removes travel, time off, and cost barriers of in-person learning
2026 Q3 Virtual Practice Management
"From Vision to Standard of Care: Implementing DPYD Testing Across Health Systems"
- Tuesday, August 11, 2026 at 2-3:15 p.m. CT, via Zoom
- Cost: FREE for members, $34 for non-members
Session description
Recent guideline recommendation changes for DPYD testing represent an opportunity for hematology/oncology pharmacists to lead precision medicine initiatives that improve patient safety and therapeutic outcomes.
This session will highlight real-world experiences from three health systems – Ochsner Health, University of Michigan, and Atrium Health – each describing their unique approaches to designing, implementing, and scaling pharmacogenomics programs, with a shared focus on pre-treatment DPYD testing prior to fluoropyrimidine chemotherapy. Attendees will gain insight into how each health system approached key operational decisions, including testing strategies (preemptive vs. reactive), vendor selection, reimbursement pathways, clinical decision support (CDS) alert design, pharmacist training and certification, governance structures, and scalable workflows across diverse care settings.
This session will provide hematology/oncology pharmacists with a comparative, pragmatic roadmap for integrating DPYD testing into a variety of practice settings.
Learning objectives
- Describe key operational components required to implement a pharmacy-led preemptive DPYD testing program within a multisite health system
- Compare preemptive versus reactive pharmacogenomic testing strategies and justify the rationale for mandatory DPYD testing prior to fluoropyrimidine therapy
- Explain how EMR integration and tiered clinical decision support tools (interruptive vs. inline alerts) support safe and scalable application of DPYD results in oncology practice
- Identify strategies to overcome common implementation barriers, including result documentation, reimbursement challenges, clinician hesitancy, and cross-site workflow variation
- Discuss the evolving role of hematology/oncology pharmacists in leading pharmacogenomics services, including education, consultative support, and governance participation
There will be 1.25 ACPE CE credits available for this session.
Meet our presenters
Gillian Bell, PharmD
Dr. Gillian Bell joined Ochsner Health as a System Clinical Pharmacogenomics Pharmacist in 2025. She completed her PharmD at the University of Tennessee College of Pharmacy and 2 years of postgraduate training in pharmacy practice and clinical pharmacogenomics at the Memphis VAMC and St. Jude Children's Research Hospital, respectively.
Serena Mitaly, PharmD
Dr. Serena Mitaly co-leads the Pharmacogenomics Program at Ochsner Health, where she drives the integration of pharmacogenomics into clinical practice. She earned her Doctor of Pharmacy from Western New England University, completed her PGY1 pharmacy residency at MedStar Washington Hospital Center, and specialized in Clinical Pharmacogenomics during her PGY2 residency at Mayo Clinic.
Grace Nyugen, PharmD, BCPS
Grace Nguyen, PharmD, BCPS, is a clinical pharmacogenomics specialist at Atrium Health Levine Cancer, where she supports the implementation of pharmacogenomics testing and pharmacogenomics clinical decision support tools. Her research focuses on evaluating the impact genotyping on cancer therapy dosing and toxicity outcomes (such as DPYD-fluoropyrimidines, UGT1A1-sacituzumab govitecan) as well as pharmacogenomic panel testing in supportive oncology.
Amy Pasternak, PharmD
Dr. Amy Pasternak is a Clinical Associate Professor and Clinical Pharmacy Specialist in Pharmacogenetics at the University of Michigan College of Pharmacy. Her research focuses on the discovery and validation of pharmacogenetic associations and evaluating the clinical impact of translating pharmacogenetics into patient care. As a clinical pharmacy specialist, she leads the implementation of pharmacogenetics into clinical workflows across the University of Michigan Health System and works as part of the clinical pharmacogenetics consult service at Michigan Medicine.
Future Virtual Practice Management sessions
Q4
- Topics and times to be determined
Are you well-versed in practice management but new to presenting live education? Virtual PM webinars are a great place to get started as a subject matter expert! Stay tuned for open calls for the rest of the 2026 Virtual Practice Management schedule.
Questions? Contact the HOPA Education team at education@hoparx.org.
Sponsor
We would like to acknowledge Genentech as the Sponsor of our 2026 Virtual Practice Management Series. Thank you for your valued support!
